NANO MRNA Co.,Ltd. (TYO:4571)

Market Cap	9.39B
Revenue (ttm)	114.00M
Net Income (ttm)	-638.00M
Shares Out	70.60M
EPS (ttm)	-9.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	182,700
Average Volume	1,252,580
Open	133.00
Previous Close	134.00
Day's Range	132.00 - 135.00
52-Week Range	113.00 - 230.00
Beta	0.35
RSI	47.77
Earnings Date	May 14, 2025

About NANO MRNA

NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment in the area of tissue generation and vaccines; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers Complex, an antibacterial ear drops; cosmetic raw material, and platelet-rich therapy. The company was for...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 18
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4571

Financial Performance

In 2023, NANO MRNA's revenue was 135.00 million, a decrease of -33.17% compared to the previous year's 202.00 million. Losses were -780.00 million, -40.46% less than in 2022.